

## Research article

## Open Access

**Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women**Carolyn J Crandall<sup>1</sup>, Mary E Sehl<sup>2</sup>, Sybil L Crawford<sup>3</sup>, Ellen B Gold<sup>4</sup>, Laurel A Habel<sup>5</sup>, Lesley M Butler<sup>6</sup>, MaryFran R Sowers<sup>7</sup>, Gail A Greendale<sup>8</sup> and Janet S Sinsheimer<sup>9</sup><sup>1</sup>Department of Internal Medicine, David Geffen School of Medicine, University of California, Los Angeles, UCLA Medicine/GIM, 911 Broxton Ave., 1st floor, Los Angeles, CA 90024, USA<sup>2</sup>Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles 2333 PVUB Los Angeles, CA 90095-7059, USA<sup>3</sup>Division of Preventive and Behavioral Medicine, University of Massachusetts Medical School, Worcester, MA, 55 Lake Ave. North, Shaw Building, Worcester, MA 01655, USA<sup>4</sup>Department of Public Health Sciences, School of Medicine, University of California, Davis, One Shields Ave., TB 168, Davis, CA 95616, USA<sup>5</sup>Division of Research, Kaiser Permanente, 2000 Broadway, Oakland, CA 94612, USA<sup>6</sup>Department of Public Health Sciences, University of California at Davis, One Shields Ave., 1616 DaVinci Court, Davis, CA 95616, USA<sup>7</sup>Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory, Rm 1846, Ann Arbor, MI 48109-2205, USA<sup>8</sup>Department of Internal Medicine, David Geffen School of Medicine at University of California, Los Angeles, 10945 Le Conte Ave., Ste. 2339, Los Angeles, CA 90095-1687, USA<sup>9</sup>Department of Human Genetics, University of California, Los Angeles, 5-357C Gonda/AV268 CHS, Los Angeles, CA 90095-1766, USACorresponding author: Carolyn J Crandall, [ccrandall@mednet.ucla.edu](mailto:ccrandall@mednet.ucla.edu)

Received: 17 Apr 2009 Revisions requested: 28 May 2009 Revisions received: 8 Jul 2009 Accepted: 27 Jul 2009 Published: 27 Jul 2009

*Breast Cancer Research* 2009, **11**:R51 (doi:10.1186/bcr2340)This article is online at: <http://breast-cancer-research.com/content/11/4/R51>

© 2009 Crandall; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.**Abstract**

**Introduction** We examined the association between mammographic density and single-nucleotide polymorphisms (SNPs) in genes encoding CYP1A1, CYP1B1, aromatase, 17 $\beta$ -HSD, ESR1, and ESR2 in pre- and early perimenopausal white, African-American, Chinese, and Japanese women.

**Methods** The Study of Women's Health Across the Nation is a longitudinal community-based cohort study. We analyzed data from 451 pre- and early perimenopausal participants of the ancillary SWAN Mammographic Density study for whom we had complete information regarding mammographic density, genotypes, and covariates. With multivariate linear regression, we examined the relation between percentage mammographic breast density (outcome) and each SNP (primary predictor), adjusting for age, race/ethnicity, parity, cigarette smoking, and body mass index (BMI).

**Results** After multivariate adjustment, the CYP1B1 rs162555 CC genotype was associated with a 9.4% higher mammographic density than the TC/TT genotype ( $P = 0.04$ ). The CYP19A1 rs936306 TT genotype was associated with 6.2% lower mammographic density than the TC/CC genotype ( $P = 0.02$ ). The positive association between CYP1A1 rs2606345 and mammographic density was significantly stronger among participants with BMI greater than 30 kg/m<sup>2</sup> than among those with BMI less than 25 kg/m<sup>2</sup> ( $P_{\text{interaction}} = 0.05$ ). Among white participants, the ESR1 rs2234693 CC genotype was associated with a 7.0% higher mammographic density than the CT/TT genotype ( $P = 0.01$ ).

**Conclusions** SNPs in certain genes encoding sex steroid metabolism enzymes and ESRs were associated with mammographic density. Because the encoded enzymes and ESR1 are expressed in breast tissue, these SNPs may influence breast cancer risk by altering mammographic density.

**Introduction**

High mammographic breast density, the density of the breast on mammography, is one of the strongest known risk factors for breast cancer [1]. High breast density (dense tissue on 50% or more of the breast) could account for up to one third

of breast cancer cases [2]. Factors such as body mass index, parity, age, smoking, and physical activity jointly account for only a small proportion of the variability in mammographic density [3]. In contrast, mammographic density has a strong genetic component. Twin studies have demonstrated that her-

BMI: body mass index; CYP: cytochrome P450; ESR: estrogen receptor; HSD: hydroxysteroid dehydrogenase; HWE: Hardy Weinberg equilibrium; SNP: single-nucleotide polymorphism; SWAN: Study of Women's Health Across the Nation.

itability (the proportion of variance attributable to genetic factors) accounts for 60% of the variance in mammographic density [4,5].

It is feasible that genetic variation in sex steroids or in estrogen receptors (ESRs) produced in breast tissue could lead to differing degrees of proliferation that may be manifest radiographically as interindividual differences in mammographic density. The presence of sex steroid metabolic enzymes and ESRs in breast tissue [6-24] suggests that local activation of estrogen to potentially reactive metabolites within breast tissue may play a role in initiating and promoting carcinogenesis [18]. Such enzymes include CYP1A1, CYP1B1, and 17 $\beta$ -hydroxysteroid dehydrogenase (17 $\beta$ -HSD). In addition to metabolizing environmental carcinogens (for example, polycyclic aromatic hydrocarbons), CYP1A1 has high activity with the 17 $\beta$ -estradiol substrate [25,26]. CYP1A1 forms mainly 2-hydroxyestrone, and to a lesser degree, some 4-hydroxyestrone, from estrone. In contrast, CYP1B1 predominantly catalyzes formation of potentially carcinogenic catechol estrogens, especially 4-hydroxyestrogens [6,26-28]. The implication of 4-hydroxy catechol estrogens in carcinogenesis suggests a key role for CYP1B1 in carcinogenesis [19,27,29,30]. *CYP19A1* is the gene encoding the aromatase enzyme that catalyzes the formation of aromatic C18 estrogens from C19 androgens [6,31]. Type I 17 $\beta$ -HSD is the enzyme responsible for interconversion of estrone and estradiol [32]. In addition to potential local effects of these enzymes on breast tissue, ESR-estrogen interactions stimulate breast epithelial cell growth [33]. Single-nucleotide polymorphisms (SNPs) in genes encoding sex steroid-metabolizing enzymes or receptors have effects on the hormonal milieu of the breast and on levels of potential mammary carcinogens [6].

A few studies have explored associations between mammographic density and SNPs in genes encoding CYP1A1, CYP1B1, aromatase, 17 $\beta$ -HSD, ESR1, and ESR2 [34-39]. However, most studies were focused on postmenopausal women [36,37]. Premenopausal breast density may be more highly heritable than is postmenopausal density [40], and some genes may be associated with premenopausal but not with postmenopausal density [4]. The goal of this study was to examine the association between mammographic density and SNPs in genes encoding CYP1A1, CYP1B1, aromatase, type I 17 $\beta$ -HSD, ESR1, and ESR2 in a group of pre- and early perimenopausal white, African-American, Chinese, and Japanese women.

## Materials and methods

To determine the association between SNPs in genes encoding sex steroid-metabolizing enzymes and ESRs and mammographic density, we used data from women who participated in the SWAN ancillary Mammographic Density Study and the SWAN Genetics Study, which are described later. All proto-

cols were IRB approved at participating sites, and all participating women provided signed, written informed consent.

### The Study of Women's Health Across the Nation (SWAN)

SWAN is a multisite longitudinal community-based cohort study of 3,302 midlife women, serving as the parent study for the Mammographic Density ancillary study. In brief, at baseline, women were aged 42 to 52 years and premenopausal (reporting no change in usual menstrual pattern) or early perimenopausal (reporting change in menstrual pattern but occurrence of menstruation in the past 3 months), had an intact uterus and one or more ovaries, were not pregnant or lactating, and were not using exogenous reproductive hormones [41]. Initiation of exogenous hormones after the baseline visit did not preclude inclusion in the longitudinal cohort study. Each of the seven study sites enrolled white women in addition to women of one other self-identified racial/ethnic group: African-American women (Boston, Detroit area, Chicago, and Pittsburgh), Japanese women (Los Angeles), Hispanic women (New Jersey), and Chinese women (Oakland, California). SWAN participants completed questionnaires and underwent fasting blood sampling annually.

### The SWAN Mammographic Density Study

Three SWAN clinical sites (Los Angeles, Oakland, Pittsburgh) participated in the SWAN Mammographic Density ancillary study, which retrieved and analyzed existing participants' mammograms that had been performed by accredited mammography facilities as a part of routine medical care.

At the time of enrollment into the ancillary study, 1,248 participants were active at the three sites. Of these, 22 (2%) women were ineligible because of bilateral breast surgery, 82 (7%) were not recruited because of having an abbreviated follow-up, and 89 (7%) refused to participate. Thus, 1,055 (85%) women were eligible and agreed to participate in the mammographic density study; of these, 1,005 women had at least one mammographic density assessment.

By using previously published methods, a single expert reviewer quantified mammographic density (that is, the percentage of the breast composed of dense tissue) [42]. The reader assessed mammographic density by using the cranio-caudal view of the mammogram of the right breast [43]. If a participant reported prior breast surgery involving the right breast, mammograms of the left breast were used for density assessments. A compensating polar planimeter was used to measure the total breast area (in square centimeters) and the area of dense breast tissue (in square centimeters). Percentage density was calculated as the area of dense breast tissue divided by the area of the breast. A repeated review of a 10% random subset of mammograms for intrarater reliability yielded an intraclass correlation coefficient for percentage mammographic density of 0.96 [43].

Our goal was to examine associations of SNPs with mammographic density among pre- and early perimenopausal participants. Of the 1,005 participants with at least one assessment of mammographic density, we chose one mammogram for each of the 643 pre- or early perimenopausal SWAN Mammographic Density study participants. If more than one mammogram was available for given participant, we selected the mammogram temporally closest to the preceding annual follow-up visit that was flanked by pre- or early perimenopausal status on the visits before and after the mammogram. For example, if a participant had mammographic density assessments from two mammograms during her premenopausal stage and one mammogram during her early perimenopausal stage, we chose a single mammogram for the participant by picking the mammogram that was temporally closest to its preceding annual follow-up visit. Mammograms that occurred more than 3 months before baseline and mammograms obtained during the use of current exogenous reproductive hormones were excluded.

### The SWAN Genetics Study

The SWAN Genetics Study genotyped 25 SNPs relating to sex-steroid metabolism and estrogen receptors (Figure 1, Table 1). Of the 1,988 women who were eligible (that is, still participating and providing blood for the SWAN parent study at the follow-up year 5 visit), 88% agreed to participate in the genetics study. Details regarding specimen collection, specimen processing, and genotyping were previously reported [44]. Genotyping was performed by using TaqMan (Roche Molecular Systems, Inc., Pleasanton, CA) and an ABI 7900 HT sequence detection system (Applied Biosystems Inc., Foster City, CA, USA).

Between three and eight SNPs per gene were selected based on use in previous genetics studies, a review of the literature, and information from gene databases (National Center for Bio-

technology SNP database [45] and Celera [46]). The original SNP selection process is discussed in the first SWAN Genetics Study manuscript [44]. The SWAN Genetics Study searched for published literature supporting the biologic significance of SNPs chosen. SNPs were chosen if they were thought potentially to influence circulating sex hormone levels [47,48] or disease patterns: breast cancer [49-51], ovarian cancer [52], and bone mineral density [53,54].

Of the 643 premenopausal or early perimenopausal SWAN participants with available mammographic density information, at least partial genotyping data were available for 463 (72%) women. For this analysis, we excluded one participant lacking genotyping data for 24 of the 25 SNPs and an additional 11 participants who were missing information for one or more covariates. Thus, the analytic sample for this study comprised the 451 pre- and early perimenopausal women for whom complete information was available regarding mammographic density, genotypes, and covariates.

### Questionnaire-based and anthropometric measures


At baseline and at each annual follow-up visit, SWAN participants were asked to complete standardized questionnaires and underwent measurement of height and weight for calculation of body mass index (BMI, weight in kilograms divided by the square of the height in meters). We took information regarding age, race/ethnicity, reproductive history, medication use, smoking, and alcohol intake from annual questionnaires.

### Statistical analysis

Allele frequencies in the SWAN Genetics Study were estimated by race/ethnicity (Mendel Version 8.0 [55]). Hardy-Weinberg equilibrium (HWE) was assessed by using Fisher's Exact tests [55]. Because of the multiple statistical tests performed, we considered a *P* value of < 0.01 as the criterion to reject the null hypothesis of HWE.

Creating a separate model for each of the 25 SNPs, we used multivariate linear regression to examine the relation between percentage mammographic breast density (outcome) and SNP (primary predictor). Based on previously published studies, we considered the following candidate covariates: age, race/ethnicity, number of live births, BMI, oral contraceptive use, menopausal hormone use, cigarette smoking, and alcohol intake) [3,43,56-68]. Of these candidate covariates, age, number of live births, and BMI were included in all models, based on previously well-established associations with mammographic density. The remaining candidate covariates (cigarette smoking, alcohol intake, oral contraceptive use, and menopausal hormone use) were evaluated for model inclusion by using backwards regression performed on data from the 643 pre- and early perimenopausal participants of the SWAN Mammographic Density study. We used a *P* value of 0.10 as the cutoff for covariate inclusion. In addition, because each site recruited a specific racial/ethnic group in addition to non-

Figure 1



Functions of SWAN genetics sex steroid metabolism enzymes and receptors. Used with permission of Sowers and colleagues [93].

**Table 1****SNPs examined in the SWAN Genetics Study**

rs Number	Other common designation of SNP	Affected alleles <sup>a</sup>	Region of affected DNA sequence	Change in amino acid
<b>17-β HSD chromosome 17q11-q21</b>				
rs615942	HSD615942 <sup>b</sup>	G/T	Missense, amino acid position 55, codon position 2, C → A exon 2	Ser → Tyr
rs592389	HSD592389	G/T	3' Near gene	N/A
rs2830	HSD17B2830	A/G	5' Untranslated region exon 1	N/A
<b>ESR1 chromosome 6q25.1</b>				
rs9340799	ESRA464, <i>Xba</i> I RFLP	A/G	Intron 1	N/A
rs2234693	ESRA418, <i>Pvu</i> II RFLP	T/C	Intron 1	N/A
rs728524	ESR728524	A/G	Intron 4	N/A
rs3798577	ESR3798577	T/C	3' Untranslated region exon 8	N/A
<b>ESR2 chromosome 14q23.2</b>				
rs1256030	ESR1256030	C/T	Intron 2	N/A
rs1255998	ESR1255998	C/G	3' Untranslated region exon 9	N/A
rs1256049	ESR1256049, V328V, <i>Rsa</i> I	G/A	Synonymous, amino acid position 328 (valine), codon position 3 exon 6	N/A
<b>CYP1A1 chromosome 15q22-q24</b>				
rs2606345	CYP2606345, -1806	C/A	Intron 1	N/A
rs4646903	CYP1A1250, <i>Msp</i> I, m1, T6235C	T/C	3' Near gene	N/A
rs1531163	CYP1531163, -11781 promoter <sup>c</sup>	A/G	Synonymous, amino acid position 294 (lysine), codon position 3 exon 8	N/A
rs1048943	CYP1048943, CYP1A1*2C, A2455G, m2, 6750 A>G	A/G	Missense, amino acid position 462, codon position 1 A → G exon 7	Ile → Val
<b>CYP1B1 chromosome 2p21</b>				
rs1800440	CYP1800440, N453S, A4390G, CYP1B1*4	A/G	Missense, amino acid position 453, codon position 2 A → G exon 3	Asn → Ser
rs162555	CYP162555 <sup>d</sup>	T/C	Intron 2	N/A
rs1056836	CYP1056836, CYP1B1*3, Leu432Val, 4326C>G, C1294G, m1	C/G	Missense, amino acid position 432, codon position 1 G → C exon 3	Val → Leu
<b>CYP19A1 chromosome 15q21.1</b>				
rs700519	CYP19R264	C/T	Missense, amino acid position 264, codon position 1 C → T exon 7	Arg → Cys
rs2414096	CYP194096	G/A	Intron 2	N/A
N/A	CYP194947, hCV8234946	A/G	Intron 1	N/A
rs1008805	CYP198805	T/C	Intron 1	N/A
rs2446405	CYP196405 <sup>a</sup>	T/A	Intron 1	N/A
rs2445759	CYP195759	G/T	Intron 1	N/A
rs936306	CYP196306	C/T	Intron 1	N/A
rs749292	CYP199292	G/A	Intron 1	N/A

<sup>a</sup>Reference (higher frequency) allele is listed first. <sup>b</sup>Encodes Coenzyme A synthase. <sup>c</sup>Encodes lectin, mannose-binding, 1-like. <sup>d</sup>Encodes LOC732 hypothetical protein. <sup>e</sup>Encodes gliomedine.

Hispanic whites, a combined variable was created for race/ethnicity and study site; this variable was included in all models. Categories for this variable were whites in Oakland, Chinese in Oakland, whites in Los Angeles, Japanese in Los Angeles, white in Pittsburgh, or African American in Pittsburgh. Age at mammogram (continuous), race/ethnicity-study site, number of live births (continuous), current cigarette smoking (yes/no), and BMI (continuous) were the covariates retained in the final models. We modeled the alleles as acting in either an additive (aa versus Aa and AA, where the effect of the Aa genotype is half the effect of the AA genotype) or recessive (aa/Aa versus AA) manner, in which A is the minor allele.

Because of prior studies showing that associations of sex steroid-related SNPs may be more evident among women with BMI greater than 25 [69], we conducted secondary analyses wherein we added an SNP\*BMI interaction term to the multivariable linear regression models. Because we suspected that the sample size of certain racial/ethnic subgroups may have been too small to allow detection of SNP\*race/ethnicity interactions, and because the allele frequencies for 13 of the 25 SNPs differed by more than 0.20 between the ethnic groups, we repeated all of our analyses in the subsample of white participants, the largest racial/ethnic subgroup. All regression analyses were performed with the software program R [70].

## Results

### Baseline characteristics of the participants

Baseline characteristics of the analytic sample (N = 451 with mammographic density, genotyping, and covariate data) are displayed in Table 2. No notable differences in characteristics were found between the overall mammographic density sample (N = 643) and the analytic sample. The median age of the participants in the analytic sample was 48.7 years (Table 2). Median BMI was 24.4 kg/m<sup>2</sup>. Mean percentage mammographic density was 43.6%. Forty-nine percent of the participants in the analytic sample were white, 24% were Chinese, 22% were Japanese, and 6% were African American. Twenty-six percent were premenopausal, and 74% were early perimenopausal at the visit immediately preceding mammography (Table 2).

### Hardy-Weinberg Equilibrium assessment

We examined allele frequencies by ethnicity (Table 3) and assessed HWE (see Table 4). Within racial/ethnic subgroups, only *CYP19A1* rs749292 showed significant deviation from HWE. Because this SNP was also the SNP with the highest frequency (8%) of missing genotypes, methodologic considerations related to genotyping of this SNP may have contributed to deviation from HWE.

### Associations between SNPs and percentage mammographic density

We examined the association between percentage mammographic breast density and each of the SNPs in models adjusted for age, race/ethnicity-study site, parity, smoking, and BMI (Tables 5 and 6).

In the fully adjusted recessive models (adjusted for age, race/ethnicity-study site, parity, smoking, and BMI), the *CYP1B1* rs162555 CC genotype was associated with 9.4% higher percentage mammographic density than the TC/TT genotype ( $P = 0.04$ ). The *CYP19A1* rs936306 TT genotype was associated with 6.2% lower percentage mammographic density than TC/CC genotype ( $P = 0.03$ ) (Table 5). In contrast to analyses restricted to white participants, *ESR1* rs2234693 was not significantly associated with mammographic density in either recessive or additive models that included the entire analytic sample (Tables 5 and 6).

### Interaction by BMI

In additive models, *CYP1A1* rs2606345 was significantly associated with BMI (1.1 kg/m<sup>2</sup> higher for each A allele;  $P = 0.03$ ) and *CYP19A1* rs2414096 (1.1 kg/m<sup>2</sup> lower for each A allele;  $P = 0.01$ ; data not shown). Similarly, in recessive models restricted to white participants, the *CYP19A1* rs749292 AA genotype was associated with a 2.1 kg/m<sup>2</sup> lower BMI compared with the GA/AA genotype ( $P = 0.05$ ), and the *CYP19A1* rs749292 AA genotype was associated with a 2.3 kg/m<sup>2</sup> lower BMI than the GA/GG genotype ( $P = 0.05$ ; data not shown).

To determine whether associations between SNPs and mammographic density varied according to BMI, we added BMI\*SNP interaction terms to multiple linear regression models that included age, race/ethnicity-study site, smoking, parity, and BMI as covariates and percentage mammographic density as the outcome (data not shown). In additive models, the *CYP1A1* rs2606345-mammographic density association was significantly different (stronger) among participants with BMIs greater than 30 kg/m<sup>2</sup> compared with participants with BMIs less than 25 kg/m<sup>2</sup> ( $P_{\text{interaction}} = 0.05$ ). Specifically, among participants with BMIs less than 25 kg/m<sup>2</sup>, percentage mammographic density was 0.57% higher for each *CYP1A1* rs2606345 C allele; in contrast, among participants with BMIs greater than 30 kg/m<sup>2</sup>, percentage mammographic density was 6.1% higher for each additional C allele. The associations of SNPs with mammographic density did not significantly differ by BMI category for *CYP19A1* rs2414096, *CYP19A1* rs749292, or *CYP19A1* rs749292. However, we may not have had adequate statistical power to detect an SNP\*BMI interaction when BMI was categorized into tertiles.

### Analyses restricted to white participants

In analyses restricted to whites (n = 219), we detected two associations that were similar to those seen in the overall ana-

**Table 2****Characteristics of the study participants: analytic sample of the current study (N = 451)**

	Mean	SD	Median	Number	%
Age at mammogram, years	48.6	2.6	48.7		
BMI, kg/m <sup>2</sup>	25.9	5.9	24.4		
<25				251	56
25–30				111	25
>30				89	20
Percentage mammographic density	43.6	19.5	44.7		
Age at first full-term birth	28.1	5.5	28.0		
Ethnicity					
African American				26	6
White				219	49
Chinese				109	24
Japanese				97	22
Study site					
Oakland				184	41
Los Angeles				169	37
Pittsburgh				98	22
Smoking currently				31	7
Menopausal status at time of mammogram					
Early perimenopausal				332	74
Premenopausal				118	26
Parity					
0				77	17
1				76	17
2				196	43
3				76	17
4				19	4
≥ 5				7	2

Baseline menopause stage information was missing for one participant whose baseline mammogram was chosen; the participant was early perimenopausal at the subsequent (first annual) visit.

lytic sample (for example, *CYP19A1* rs936306 in recessive models, *CYP19A1* rs2414096 in additive models). In white participants, the *ESR1* rs2234693 CC genotype was associated with a 7.0% higher percentage mammographic density than the CT/TT genotype ( $P = 0.01$ ; Table 5); this finding was also apparent in additive models ( $P = 0.01$ ; Table 6). The association between *ESR1* rs2234693 and mammographic density varied by ethnicity; the association was stronger among whites than among Japanese (interaction  $P$  value, 0.09) or Chinese (interaction  $P$  value, 0.03) participants.

## Discussion

In pre- and early perimenopausal women, SNPs involving *CYP1B1* (rs162555 CC genotype), *CYP19A1* (rs936306 TT/CC genotype), and *ESR1* (rs2234693 CC genotype) were each significantly positively associated with mammographic density. Associations between several SNPs (*CYP1A1* rs2606345, *CYP19A1* rs749292, *CYP19A1* rs2414096) and mammographic density were attenuated after adjustment for BMI. Percentage mammographic density varied at least 3% per allele for the statistically significant associations. These differences in mammographic density according to genotype are of a clinically relevant mag-

**Table 3****Allele frequencies of SWAN Genetics Study participants by race/ethnicity**

Locus	Allele	Estimated frequencies				
		All	African	White	Chinese	Japanese
<b>17<math>\beta</math>-HSD</b>						
rs615942	G	0.52	0.64	0.47	0.55	0.56
	T	0.48	0.36	0.53	0.45	0.44
rs592389	A	0.50	0.41	0.475	0.56	0.56
	C	0.50	0.59	0.53	0.44	0.44
rs2830	A	0.50	0.59	0.53	0.44	0.44
	G	0.50	0.41	0.47	0.56	0.56
<b>ESR1</b>						
rs9340799	A	0.72	0.73	0.65	0.77	0.82
	G	0.28	0.27	0.35	0.23	0.18
rs2234693	C	0.46	0.46	0.46	0.41	0.48
	T	0.54	0.54	0.54	0.59	0.52
rs728524	A	0.89	0.76	0.98	0.81	0.81
	G	0.11	0.24	0.02	0.19	0.188
rs3798577	C	0.46	0.41	0.48	0.45	0.45
	T	0.54	0.59	0.52	0.55	0.55
<b>ESR2</b>						
rs1256030	C	0.61	0.75	0.57	0.70	0.58
	T	0.39	0.25	0.43	0.30	0.42
rs1255998	C	0.68	0.50	0.89	0.37	0.54
	G	0.32	0.50	0.11	0.63	0.46
rs1256049	A	0.18	0.11	0.02	0.45	0.30
	G	0.82	0.89	0.98	0.55	0.70
<b>CYP1A1</b>						
rs2606345	A	0.37	0.18	0.66	0.06	0.05
	C	0.63	0.82	0.34	0.94	0.95
rs4646903	A	0.75	0.71	0.89	0.54	0.61
	G	0.25	0.29	0.11	0.46	0.39
rs1531163	A	0.88	0.66	0.95	0.84	0.80
	G	0.12	0.34	0.05	0.16	0.20
rs1048943	A	0.88	0.98	0.96	0.75	0.76
	G	0.12	0.02	0.04	0.25	0.24
<b>CYP1B1</b>						
rs1800440	A	0.89	0.90	0.80	1.00	1.00
	G	0.11	0.10	0.20	0.004	0.006
rs162555	C	0.12	0.16	0.19	0.04	0.01
	T	0.88	0.84	0.81	0.96	0.99
rs1056836	C	0.69	0.33	0.59	0.88	0.86
	G	0.31	0.67	0.41	0.12	0.14

Table 3 (Continued)

## Allele frequencies of SWAN Genetics Study participants by race/ethnicity

CYP19						
rs700519	A	0.12	0.13	0.04	0.14	0.29
	G	0.88	0.88	0.96	0.86	0.71
rs2414096	A	0.43	0.25	0.50	0.46	0.32
	G	0.57	0.75	0.50	0.54	0.68
4947 <sup>a</sup>	A	0.52	0.71	0.55	0.39	0.49
	G	0.48	0.29	0.45	0.61	0.51
rs1008805	C	0.36	0.16	0.42	0.28	0.37
	T	0.64	0.84	0.58	0.72	0.63
rs2446405	A	0.32	0.52	0.18	0.47	0.45
	T	0.68	0.48	0.82	0.53	0.55
rs936306	C	0.73	0.40	0.85	0.70	0.60
	T	0.27	0.60	0.15	0.30	0.40
rs2445759	G	0.96	0.92	0.93	1.00	1.00
	T	0.04	0.08	0.07	0.004	0.003
rs749292	A	0.44	0.51	0.44	0.50	0.36
	G	0.56	0.49	0.56	0.50	0.64

<sup>a</sup>No corresponding dbSNP rs number; commonly referred to as CYP194947.

nitude, given that each 1% increment in mammographic density is associated with a 2% higher relative risk of breast cancer [2]. Several SNP-mammographic density associations varied significantly by ethnicity.

Several of our findings are novel. As far as we know, other publications have not reported information regarding associations between mammographic density and the following SNPs: *17β-HSD* rs615942, *17β-HSD* rs592389, *17β-HSD* rs2830, *ESR1* rs728524, *ESR1* rs3798577, *ESR2* rs1256030, *ESR2* rs1255998, *ESR2* rs1256049, *CYP1B1* rs162555, *CYP1B1* rs1800440, *CYP19A1* rs700519, *CYP19A1* rs2446405, *CYP19A1* rs2445759, *CYP19A1* rs1008805, *CYP19A1* rs936306, *CYP19A1* rs2414096, *CYP19A1* rs749292, *CYP19A1* rs1531163, or *CYP1A1* rs2606345.

Our finding of an association between *ESR1* rs2234693 and mammographic density among white women conflicts with some prior studies. The association between *ESR1* rs2234693 and mammographic density was described in three reports from the EPIC study. In the first EPIC report, the T allele was associated with higher mammographic density [39], whereas in this study, the CC genotype is associated with higher mammographic density.

The second EPIC analysis found a statistically significant difference in mammographic density between hormone therapy users and never-users of hormone therapy among women the CT or TT genotype, but not among those with the CC genotype [71].

The third EPIC analysis reported no association between *ESR1* rs2234693 and mammographic density [36]; the discrepancy among studies may be because the previous study used a different mammographic density measurement technique, had a less heterogeneous study population, and focused on postmenopausal women.

We found an association between *CYP1B1* rs1056836 and mammographic density that neared statistical significance only before adjustment, but not after adjustment, for BMI. These results may be consistent with three previously published studies [35,36,38].

A cross-sectional observational European study of white women found statistically significantly higher mammographic density in carriers of at least one *ESR1* rs9340799 A allele [39]. Although we had similar results, our findings were not statistically significant, possibly because of the smaller number of participants in our study or the younger age of our participants.



**Table 4****Hardy-Weinberg equilibrium evaluation by race/ethnicity**

Locus	All		African		White		Chinese		Japanese	
	<i>P</i> value	Number	<i>P</i> value	Number	<i>P</i> value	Number	<i>P</i> value	Number	<i>P</i> value	Number
HSD										
rs615942	0.0741	716	1	56	0.0691	364	0.2962	139	0.632	157
rs592389	0.0462	714	0.4159	56	0.075	361	0.3061	138	0.7462	156
rs2830	0.0356	715	0.4074	56	0.1147	362	0.1189	139	0.7504	156
ESR1										
rs9340799	0.5221	720	0.1818	56	0.1726	365	0.6308	140	0.5958	157
rs2234693	0.8786	718	0.5964	56	0.5327	364	1	139	0.4255	157
rs728524	0.0724	719	0.4825	56	1	364	1	140	0.7874	157
rs3798577	0.9362	715	0.7783	55	0.8299	363	1	139	1	156
ESR2										
rs1256030	0.6411	715	0.0811	56	1	363	0.1591	140	0.7379	154
rs1255998	<0.00005	712	0.2985	56	0.41	361	0.199	138	1	155
rs1256049	<0.00005	679	1	46	0.1804	344	0.3854	132	0.5638	155
CYP1A1										
rs2606345	<0.00005	715	0.6693	55	0.9088	360	1	141	1	157
rs4646903	<0.00005	706	0.7502	55	0.4137	356	1	138	0.1252	155
rs1531163	0.0092	712	0.5642	56	0.5508	359	0.3384	139	0.3173	156
rs1048943	0.0001	714	1	56	1	362	0.6582	138	0.0452	156
CYP1B1										
rs1800440	<0.00005	685	0.347	47	0.0629	345	1	135	1	156
rs162555	0.0033	716	1	56	0.2346	364	0.1518	138	1	156
rs1056836	<0.00005	704	0.0591	53	0.2778	355	1	139	0.3159	155
CYP19										
rs700519	0.0756	712	0.1854	56	1	360	0.0694	138	0.7032	156
rs2414096	0.9384	719	0.7184	56	0.1193	365	0.2394	141	0.3603	155
4947 <sup>a  </sup>	<0.00005	654	0.0195	41	0.5857	344	<0.00005	129	<0.00005	138
rs1008805	0.7465	717	0.6143	56	0.2444	364	0.2942	140	0.7366	155
rs2446405	0.0376	716	0.7845	55	0.7187	364	0.6048	139	0.7456	156
rs936306	0.0031	717	1	56	0.3074	364	0.552	140	0.7366	155
rs2445759	1	682	1	45	1	344	1	135	1	156
rs749292	0.6463	715	0.4183	55	0.2371	361	0.6075	141	1	156

<sup>a</sup>No corresponding dbSNP rs number; commonly referred to as CYP19A4947.

**Table 5****Percentage mammographic density as a function of single-nucleotide polymorphism: recessive models<sup>a</sup>**

Locus	Entire analytic sample (N = 451)			Whites only (N = 219)		
	$\beta$	SD	<i>P</i> value	$\beta$	SD	<i>P</i> value
<b>17-<math>\beta</math> HSD</b>						
rs615942 G	-0.18	1.73	0.92	0.78	2.55	0.76
rs592389 A	-0.81	1.71	0.64	0.97	2.55	0.70
rs2830 A	1.75	1.65	0.29	2.69	2.59	0.30
<b>ESR1</b>						
rs9340799 A	4.40	2.79	0.12	6.67	3.50	0.06
rs2234693 T	3.37	1.81	0.06	7.04	2.67	<b>0.01</b>
rs728524 A	1.43	5.33	0.79	N/A	N/A	N/A
rs3798577 T	3.04	1.79	0.09	1.14	2.75	0.68
<b>ESR2</b>						
rs1256030 C	0.72	2.10	0.73	0.80	2.94	0.79
rs1255998 C	-0.14	2.25	0.95	-11.59	11.92	0.33
rs1256049 G	-5.58	3.21	0.08	-6.98	16.85	0.68
<b>CYP1A1</b>						
rs2606345 C	-0.21	2.15	0.92	-0.09	2.32	0.97
rs4646903 A	0.83	2.45	0.73	-1.11	6.45	0.99
rs1531163 A	0.09	4.47	0.98	-5.50	16.87	0.74
rs1048943 A	1.14	3.99	0.77	N/A	N/A	N/A
<b>CYP1B1</b>						
rs1800440 A	-2.29	3.92	0.56	-1.35	4.50	0.76
rs162555 T	9.36	4.62	<b>0.04</b>	8.23	5.45	0.13
rs1056836 C	2.48	2.51	0.33	1.37	3.07	0.66
<b>CYP19A1</b>						
rs700519 G	-4.59	6.12	0.45	N/A	N/A	N/A
rs2414096 G	-0.83	1.94	0.67	1.33	2.81	0.64
CYP194947 <sup>†</sup> A	1.30	1.68	0.44	3.93	2.83	0.17
rs1008805 T	-3.56	2.24	0.11	-2.36	3.07	0.44
rs2446405 T	1.99	2.31	0.39	-4.96	5.78	0.39
rs936306 C	-6.17	2.82	<b>0.03</b>	-16.36	5.96	<b>0.01</b>
rs2445759 G	-7.30	9.18	0.43	-10.36	11.98	0.39
rs749292 G	0.40	1.93	0.84	3.53	2.98	0.24

<sup>a</sup>Reference allele was the allele with the higher frequency in the overall analytic sample and is indicated in the first column for each SNP.

<sup>b</sup>Because each site recruited a specific racial/ethnic group in addition to non-Hispanic whites, a combined variable was created for race/ethnicity and study site.

**Table 6****Percentage mammographic density as a function of single-nucleotide polymorphism: additive models<sup>a</sup>**

Entire analytic sample (N = 451)				Whites only (N = 219)		
Age, race/ethnicity-study site <sup>b</sup> , parity, smoking, body mass index				Age, study site, parity, smoking, body mass index		
LOCUS	$\beta$	SD	<i>P</i> value	$\beta$	SD	<i>P</i> value
<b>17-<math>\beta</math> HSD</b>						
rs615942 G	-0.68	1.02	0.50	-0.68	1.55	0.66
rs592389 G	-1.01	1.02	0.32	-0.59	1.56	0.71
rs2830 A	1.05	1.01	0.30	0.63	1.56	0.69
<b>ESR1</b>						
rs9340799 A	1.58	1.22	0.20	3.11	1.77	0.08
rs2234693 T	1.44	1.06	0.18	4.08	1.61	<b>0.01</b>
rs728524 A	3.35	1.77	0.06	-9.14	6.50	0.16
rs3798577 T	1.01	1.05	0.34	-0.36	1.65	0.83
<b>ESR2</b>						
rs1256030 C	0.79	1.10	0.47	0.76	1.64	0.64
rs1255998 C	-0.42	1.30	0.75	-2.38	2.61	0.36
rs1256049 G	-1.02	1.53	0.51	-2.28	4.34	0.60
<b>CYP1A1</b>						
rs2606345 C	-1.32	1.40	0.34	-1.00	1.69	0.56
rs4646903 T	1.49	1.19	0.21	1.34	2.25	0.55
rs1531163 A	-0.33	1.60	0.84	-4.51	3.70	0.23
rs1048943 A	0.20	1.55	0.90	1.19	4.05	0.77
<b>CYP1B1</b>						
rs1800440 A	0.72	1.58	0.65	1.73	1.84	0.35
rs162555 T	0.52	1.64	0.75	0.45	2.01	0.82
rs1056836 C	-0.37	1.22	0.78	-1.39	1.62	0.39
<b>CYP19A1</b>						
rs700519 C	1.59	1.72	0.36	-3.46	4.00	0.39
rs2414096 G	0.77	1.11	0.49	2.75	1.74	0.12
CYP194947 <sup>c</sup> A	0.99	0.96	0.30	2.67	1.62	0.10
rs1008805 T	-0.02	1.12	0.99	-0.65	1.66	0.70
rs2446405 T	0.81	1.20	0.50	-3.02	2.05	0.14
rs936306 C	-0.92	1.25	0.46	-3.67	2.12	0.09
rs2445759 G	-3.47	2.36	0.14	-5.19	2.86	0.07
rs749292 G	0.67	1.08	0.53	2.83	1.67	0.09

<sup>a</sup>Reference allele was the allele with the higher frequency in the overall analytic sample and is indicated in the first column for each SNP. <sup>b</sup>Because each site recruited a specific racial/ethnic group in addition to non-Hispanic whites, a combined variable was created for race/ethnicity and study site. <sup>c</sup>No corresponding dbSNP rs number; commonly referred to as CYP194947.

The other SNPs involved in sex steroid metabolism or estrogen receptors were not significantly associated with mammographic density in the present study. As with our study, past studies reported absence of an association between mammographic density and *CYP1A1* rs1048943 and *CYP1A1* rs4646903 [35,38].

Although previously published studies have not included a systematic examination of sex steroid metabolism SNPs and mammographic density, some previously studied SNPs may be linked with the SNPs that we examined. We searched Haploview version 4.1 (Daly Lab, Cambridge, MA) with Hapmap genotype data to search for information regarding linkage disequilibrium for each of the three SNPs that we found to be associated with mammographic density and other SNPs previously studied in relation to mammographic density. Linkage disequilibrium  $R^2$  values for *ESR1A1* rs2234693 (which we found to be associated with mammographic density) and rs9340799 (which prior studies found to be associated with mammographic density) range from 0.234 to 0.55, depending on the ethnic group. For *CYP19A1* rs936306 (which we found to be associated with mammographic density) and rs10046 (which prior studies found not to be associated with mammographic density),  $R^2$  values range from 0.017 to 0.193. Linkage-disequilibrium information is not currently available for *CYP1B1* rs162555 on Hapmap. Although LD information was not available for rs162555, we note that its chromosomal location is not close to the other two previously studied *CYP1B1* SNPs.

Our findings have a biologic rationale. A local influence of sex steroid metabolism SNPs on breast tissue is suggested by prior breast cancer studies. For example, *ESR1* rs2234693 has been associated with duration of breast cancer survival [72], degree of breast cancer differentiation [73], age at breast cancer diagnosis [74], and receptor status of breast cancer tumors [75,76]. Likewise, *CYP19A1* rs936306 may be associated with breast cancer disease-free survival [77]. Case-control studies of breast cancer risk related to *ESR1* rs2234693 [73,76,78-87] and in relation to *CYP19A1* rs936306 [77,88] are conflicting. Inconsistent results of breast cancer case-control studies are likely due to differences in ethnicity and menopausal status of participants across studies. Reasons exist to suspect that associations of SNPs with mammographic density may vary by BMI, as we found for *CYP1A1* rs2606345. Sex steroid metabolism (for example, peripheral aromatization of androstenedione) varies by BMI, so that effects of sex steroid SNPs on breast tissue may be more pronounced among obese women. Although prior studies have not examined whether associations of *CYP1A1* rs2606345 with mammographic density vary by BMI, a prior study reported that the association of an *ESR1* SNP with increased breast cancer risk was apparent only among women with BMI greater than 25 kg/m<sup>2</sup> [69].

Strengths of our study included its multiethnic study population, use of validated and reproducible mammographic density-assessment techniques, rigorous attention to genotyping methods, and collection of detailed information regarding key covariates related to mammographic density. However, this study did not directly assess sex steroid activity in breast tissue samples. Furthermore, although our sample size was relatively large, its heterogeneity may have precluded detection of statistically significant race-specific associations or interactions of SNPs with mammographic density. Finally, the observational study design precluded coordination of mammographic density with menstrual-cycle phase. Relations between SNPs and mammographic density may have been diluted because we analyzed mammograms taken during varying menstrual phases. Breasts are more radiographically dense during the luteal phase [89-91], although a recent study found that variation in mammographic density over the menstrual cycle may be subtle (that is, may not be statistically significant) [92].

## Conclusions

In conclusion, SNPs involving sex steroid metabolism enzymes and *ESR1* may be associated with mammographic density in pre- and early perimenopausal women. Future studies relating these SNPs to mammographic density not only should adjust for BMI but also should consider interactions by BMI. The mechanisms underlying the association (for example, increased proliferation of epithelial and stromal cells) require elucidation. Because these enzymes and *ESR1* are expressed in target tissues, these SNPs (or genetic factors with which they are in linkage disequilibrium) may alter breast cancer risk by altering mammographic density. These findings inform the understanding of biologic influences on mammographic density, a strong risk factor for breast cancer.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

CC contributed to study conception, study design, analysis and interpretation of data, manuscript drafting, and revision. JS and MS contributed to study design. MS, SC, EG, LH, LB, MS, GG, and JS contributed to analysis and interpretation of data and manuscript revision.

## Acknowledgements

The Study of Women's Health Across the Nation (SWAN) has grant support from the National Institutes of Health (NIH), DHHS, through the National Institute on Aging (NIA), the National Institute of Nursing Research (NINR), and the NIH Office of Research on Women's Health (ORWH) (grants NR004061; AG012505, AG012535, AG012531, AG012539, AG012546, AG012553, AG012554, AG012495, AG017719). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NIA, NINR, ORWH, or the NIH. Dr. Crandall's work was supported by National Institutes of Health research grant 5K12 AG01004-08 from the National Institute on Aging and by the Michael Parr Fund for

Women's Health Research and Education at the Iris Cantor-UCLA Women's Health Center.

Clinical Centers: University of Michigan, Ann Arbor, MaryFran Sowers, PI; Massachusetts General Hospital, Boston, MA, Robert Neer, PI 1994–1999; Joel Finkelstein, PI 1999 to present; Rush University, Rush University Medical Center, Chicago, IL, Lynda Powell, PI; University of California, Davis/Kaiser, Ellen Gold, PI; University of California, Los Angeles, Gail Greendale, PI; University of Medicine and Dentistry, New Jersey Medical School, Newark, Gerson Weiss, PI 1994 to 2004; Nanette Santoro, PI 2004 to present; and the University of Pittsburgh, Pittsburgh, PA, Karen Matthews, PI.

NIH Program Office: National Institute on Aging, Bethesda, MD, Marcia Ory 1994 to 2001; Sherry Sherman, 1994 to present; National Institute of Nursing Research, Bethesda, MD, Program Officers.

Central Laboratory: University of Michigan, Ann Arbor, Daniel McConnell (Central Ligand Assay Satellite Services).

SWAN Repository: University of Michigan, Ann Arbor, MaryFran Sowers.

Coordinating Center: New England Research Institutes, Watertown, MA, Sonja McKinlay, PI 1995 to 2001; University of Pittsburgh, Pittsburgh, PA, Kim Sutton-Tyrrell, PI 2001 to present.

Steering Committee: Chris Gallagher, Chair

Susan Johnson, Chair

We thank the study staff at each site and all the women who participated in SWAN.

## References

- American Cancer Society: **Breast Cancer Facts & Figures 2007–2008**. Atlanta, Georgia, American Cancer Society Inc; 2007.
- Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Trichler DL, Yaffe MJ: **Quantitative classification of mammographic densities and breast cancer risk: Results from the Canadian National Breast Screening Study**. *J Natl Cancer Inst* 1995, **87**:670-675.
- Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA: **Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States)**. *Cancer Causes Control* 2000, **11**:653-662.
- Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, Giles GG, Trichler D, Chiarelli A, Yaffe MJ, Hopper JL: **Heritability of mammographic density, a risk factor for breast cancer**. *N Engl J Med* 2002, **347**:886-894.
- Ursin G, Lillie EO, Lee E, Cockburn M, Schork NJ, Cozen W, Parisky YR, Hamilton AS, Astrahan MA, Mack T: **The relative importance of genetics and environment on mammographic density**. *Cancer Epidemiol Biomarkers Prev* 2009, **18**:102-112.
- Mitrunen K, Hirvonen A: **Molecular epidemiology of sporadic breast cancer: the role of polymorphic genes involved in oestrogen biosynthesis and metabolism**. *Mutat Res* 2003, **544**:9-41.
- Hellmold H, Rylander T, Magnusson M, Reihner E, Warner M, Gustafsson JA: **Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammoplasties**. *J Clin Endocrinol Metab* 1998, **83**:886-895.
- Honma N, Takubo K, Sawabe M, Arai T, Akiyama F, Sakamoto G, Utsumi T, Yoshimura N, Harada N: **Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years**. *J Clin Endocrinol Metab* 2006, **91**:607-613.
- Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, Vihko R, Bulun SE, Silverberg SG, Nagura H: **Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma**. *J Clin Endocrinol Metab* 1996, **81**:4042-4046.
- Sasano H, Nagura H, Harada N, Goukon Y, Kimura M: **Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders**. *Hum Pathol* 1994, **25**:530-535.
- Shibuya R, Suzuki T, Miki Y, Yoshida K, Moriya T, Ono K, Akahira J, Ishida T, Hirakawa H, Evans DB, Sasano H: **Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast**. *Endocr Relat Cancer* 2008, **15**:113-124.
- Singh N, Mitra AK, Garg VK, Agarwal A, Sharma M, Chaturvedi R, Rath SK: **Association of CYP1A1 polymorphisms with breast cancer in North Indian women**. *Oncol Res* 2007, **16**:587-597.
- Song D, Liu G, Luu-The V, Zhao D, Wang L, Zhang H, Xueling G, Li S, Desy L, Labrie F, Pelletier G: **Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer: an immunocytochemical study**. *J Steroid Biochem Mol Biol* 2006, **101**:136-144.
- McKay JA, Melvin WT, Ah-See AK, Ewen SW, Greenlee WF, Marcus CB, Burke MD, Murray GI: **Expression of cytochrome P450 CYP1B1 in breast cancer**. *FEBS Lett* 1995, **374**:270-272.
- Haas S, Pierl C, Harth V, Pesch B, Rabstein S, Bruning T, Ko Y, Hamann U, Justenhoven C, Brauch H, Fischer HP: **Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas**. *Int J Cancer* 2006, **119**:1785-1791.
- Singh S, Chakravarti D, Edney JA, Hollins RR, Johnson PJ, West WW, Higginbotham SM, Cavalieri EL, Rogan EG: **Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma**. *Oncol Rep* 2005, **14**:1091-1096.
- Licznerska BE, Wegman PP, Nordenskjold B, Wingren S: **In situ levels of oestrogen producing enzymes and its prognostic significance in postmenopausal breast cancer patients**. *Breast Cancer Res Treat* 2007, **112**:15-23.
- Modugno F, Knoll C, Kanbour-Shakir A, Romkes M: **A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis**. *Breast Cancer Res Treat* 2003, **82**:191-197.
- Sasano H, Suzuki T, Nakata T, Moriya T: **New development in intracrinology of breast carcinoma**. *Breast Cancer* 2006, **13**:129-136.
- Wen W, Ren Z, Shu XO, Cai Q, Ye C, Gao YT, Zheng W: **Expression of cytochrome P450 1B1 and catechol-O-methyltransferase in breast tissue and their associations with breast cancer risk**. *Cancer Epidemiol Biomarkers Prev* 2007, **16**:917-920.
- Iscan M, Klaavuniemi T, Coban T, Kapucuoglu N, Pelkonen O, Raunio H: **The expression of cytochrome P450 enzymes in human breast tumours and normal breast tissue**. *Breast Cancer Res Treat* 2001, **70**:47-54.
- Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS: **Expression of cytochromes P450 in human breast tissue and tumors**. *Drug Metab Dispos* 1996, **24**:899-905.
- Liehr JG, Ricci MJ: **4-Hydroxylation of estrogens as marker of human mammary tumors**. *Proc Natl Acad Sci USA* 1996, **93**:3294-3296.
- Sommer S, Fuqua SA: **Estrogen receptor and breast cancer**. *Semin Cancer Biol* 2001, **11**:339-352.
- Perera FP: **Environment and cancer: who are susceptible?** *Science* 1997, **278**:1068-1073.
- Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: **Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms**. *Endocrinology* 2003, **144**:3382-3398.
- Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR: **17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1**. *Proc Natl Acad Sci USA* 1996, **93**:9776-9781.
- Yager JD, Liehr JG: **Molecular mechanisms of estrogen carcinogenesis**. *Annu Rev Pharmacol Toxicol* 1996, **36**:203-232.
- Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF: **Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity**. *Cancer Res* 2000, **60**:3440-3444.
- Shimada T, Fujii-Kuriyama Y: **Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1**. *Cancer Sci* 2004, **95**:1-6.

31. Kronenberg H, Williams RH: **Williams Textbook of Endocrinology**. 11th edition. Philadelphia: Saunders/Elsevier; 2008.
32. Kendall A, Folkard EJ, Dowsett M: **Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer**. *J Steroid Biochem Mol Biol* 2007, **103**:99-109.
33. Rayter Z: **Steroid receptors in breast cancer**. *Br J Surg* 1991, **78**:528-535.
34. Haiman CA, Bernstein L, Berg D, Ingles SA, Salane M, Ursin G: **Genetic determinants of mammographic density**. *Breast Cancer Res* 2002, **4**:R5.
35. Haiman CA, Hankinson SE, De Vivo I, Guillemette C, Ishibe N, Hunter DJ, Byrne C: **Polymorphisms in steroid hormone pathway genes and mammographic density**. *Breast Cancer Res Treat* 2003, **77**:27-36.
36. Warren R, Skinner J, Sala E, Denton E, Dowsett M, Folkard E, Healey CS, Dunning A, Doody D, Ponder B, Luben RN, Day NE, Easton D: **Associations among mammographic density, circulating sex hormones, and polymorphisms in sex hormone metabolism genes in postmenopausal women**. *Cancer Epidemiol Biomarkers Prev* 2006, **15**:1502-1508.
37. Lord SJ, Mack WJ, Berg D, Van Den, Pike MC, Ingles SA, Haiman CA, Wang W, Parisky YR, Hodis HN, Ursin G: **Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: Results from a pilot study**. *Breast Cancer Res* 2005, **7**:R336-R344.
38. Maskarinec G, Lurie G, Williams AE, Le Marchand L: **An investigation of mammographic density and gene variants in healthy women**. *Int J Cancer* 2004, **112**:683-688.
39. van Duijnhoven FJ, Bezemer ID, Peeters PH, Roest M, Uitterlinden AG, Grobbee DE, van Gils CH: **Polymorphisms in the estrogen receptor alpha gene and mammographic density**. *Cancer Epidemiol Biomarkers Prev* 2005, **14**:2655-2660.
40. Vachon CM, Sellers TA, Pankratz VS: **Mammographic density of the breast**. *N Engl J Med* 2003, **348**:174-175. author reply 174-175
41. Sowers M, Crawford S, Morgenstein D, Gold E, Greendale GA, Evans D, Neer R, Matthews K, Sherman S, Lo A, Weiss G, Kelsey J: **Design, survey sampling and recruitment Methods of SWAN: a multi-center, multi-ethnic, community-based cohort study of women and the menopausal transition**. In *Menopause* Edited by: Lobos R, Marcus R, Kelsey JL. New York: Academic Press; 2000:175-188.
42. Habel LA, Dignam JJ, Land SR, Salane M, Capra AM, Julian TB: **Mammographic density and breast cancer after ductal carcinoma in situ**. *J Natl Cancer Inst* 2004, **96**:1467-1472.
43. Habel LA, Capra AM, Oestreicher N, Greendale GA, Cauley JA, Bromberger J, Crandall CJ, Gold EB, Modugno F, Salane M, Quesenberry C, Sternfeld B: **Mammographic density in a multi-ethnic cohort**. *Menopause* 2007, **14**:891-899.
44. Kardia SR, Chu J, Sowers MR: **Characterizing variation in sex steroid hormone pathway genes in women of 4 races/ethnicities: the Study of Women's Health Across the Nation (SWAN)**. *Am J Med* 2006, **119**:S3-S15.
45. **National Center for Biotechnology SNP database** [<http://www.ncbi.nlm.nih.gov/SNP>]
46. **Celera** [<http://www.celera.com>]
47. Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A: **Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women**. *Cancer Epidemiol Biomarkers Prev* 2004, **13**:94-101.
48. Baghaei F, Rosmond R, Westberg L, Hellstrand M, Eriksson E, Holm G, Bjorntorp P: **The CYP19 gene and associations with androgens and abdominal obesity in premenopausal women**. *Obes Res* 2003, **11**:578-585.
49. Haiman CA, Stram DO, Pike MC, Kolonel LN, Burt NP, Altshuler D, Hirschhorn J, Henderson BE: **A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort**. *Hum Mol Genet* 2003, **12**:2679-2692.
50. Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang H, Chen M, Lippert R, Halldorsson BV, Woodworth B, White T, Clark AG, Parl FF, Broder S, Dean M, Offit K: **Estrogen receptor genotypes and haplotypes associated with breast cancer risk**. *Cancer Res* 2004, **64**:8891-8900.
51. Bailey LR, Roodi N, Dupont WD, Parl FF: **Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer**. *Cancer Res* 1998, **58**:5038-5041.
52. Aktas D, Guney I, Alikasifoglu M, Yuce K, Tuncbilek E, Ayhan A: **CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm**. *Gynecol Oncol* 2002, **86**:124-128.
53. Kobayashi S, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H: **Association of bone mineral density with polymorphism of the estrogen receptor gene**. *J Bone Miner Res* 1996, **11**:306-311.
54. Willing M, Sowers M, Aron D, Clark MK, Burns T, Bunten C, Crutchfield M, D'Agostino D, Jannausch M: **Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction**. *J Bone Miner Res* 1998, **13**:695-705.
55. Lange K, Cantor R, Horvath S, Perola M, Sabatti C, Sinsheimer J, Sobel E: **Mendel version 4.0: A complete package for the exact genetic analysis of discrete traits in pedigree and population data sets**. *Am J Hum Genet* 2001, **69**:A1886.
56. Gapstur SM, Lopez P, Colangelo LA, Wolfman J, Van Horn L, Hendrick RE: **Associations of breast cancer risk factors with breast density in Hispanic women**. *Cancer Epidemiol Biomarkers Prev* 2003, **12**:1074-1080.
57. Maskarinec G, Meng L, Ursin G: **Ethnic differences in mammographic densities**. *Int J Epidemiol* 2001, **30**:959-965.
58. Maskarinec G, Pagano I, Lurie G, Wilkens LR, Kolonel LN: **Mammographic density and breast cancer risk: the multiethnic cohort study**. *Am J Epidemiol* 2005, **162**:743-752.
59. Martin C, Peck J, Pisano E, Davis C, McTiernan A, Hulka B: **Prior HRT use, ethnicity and mammographic density**. *Ann Epidemiol* 2000, **10**:461-462.
60. Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E, Cummings SR: **Are breast density and bone mineral density independent risk factors for breast cancer?** *J Natl Cancer Inst* 2005, **97**:368-374.
61. Riza E, Dos Santos Silva I, De Stavola B, Perry N, Karadedou-Zafiriadou E, Linos D, Remoundos DD, Linos A: **Correlates of high-density mammographic parenchymal patterns by menopausal status in a rural population in Northern Greece**. *Eur J Cancer* 2005, **41**:590-600.
62. Hofling M, Carlstrom K, Svane G, Azavedo E, Kloosterboer H, Von Schoultz B: **Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels: an association with mammographic density**. *Gynecol Endocrinol* 2005, **20**:110-115.
63. Heng D, Gao F, Jong R, Fishell E, Yaffe M, Martin L, Li T, Stone J, Sun L, Hopper J, Boyd NF: **Risk factors for breast cancer associated with mammographic features in Singaporean Chinese women**. *Cancer Epidemiol Biomarkers Prev* 2004, **13**:1751-1758.
64. Masala G, Ambrogetti D, Assedi M, Giorgi D, Del Turco MR, Palli D: **Dietary and lifestyle determinants of mammographic breast density: a longitudinal study in a Mediterranean population**. *Int J Cancer* 2006, **118**:1782-1789.
65. Jeffreys M, Warren R, Gunnell D, McCarron P, Smith GD: **Life course breast cancer risk factors and adult breast density (United Kingdom)**. *Cancer Causes Control* 2004, **15**:947-955.
66. McCormack VA, dos Santos Silva I, De Stavola BL, Perry N, Vinnicombe S, Swerdlow AJ, Hardy R, Kuh D: **Life-course body size and perimenopausal mammographic parenchymal patterns in the MRC 1946 British birth cohort**. *Br J Cancer* 2003, **89**:852-859.
67. Butler LM, Gold EB, Greendale GA, Crandall CJ, Modugno F, Oestreicher N, Quesenberry CP Jr, Habel LA: **Menstrual and reproductive factors in relation to mammographic density: the Study of Women's Health Across the Nation (SWAN)**. *Breast Cancer Res Treat* 2008, **112**:165-174.
68. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G: **Postmenopausal hormone therapy and change in mammographic density**. *J Natl Cancer Inst* 2003, **95**:30-37.
69. Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AE: **Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population**. *Arch Toxicol* 2002, **76**:643-649.

70. R Development Core Team: **R: A Language and Environment for Statistical Computing**. R Foundation for Statistical Computing, Vienna, Austria; 2008.
71. van Duijnhoven FJ, Peeters PH, Warren RM, Bingham SA, Uitterlinden AG, van Noord PA, Monninkhof EM, Grobbee DE, van Gils CH: **Influence of estrogen receptor alpha and progesterone receptor polymorphisms on the effects of hormone therapy on mammographic density**. *Cancer Epidemiol Biomarkers Prev* 2006, **15**:462-467.
72. Boyapati SM, Shu XO, Ruan ZX, Cai Q, Smith JR, Wen W, Gao YT, Zheng W: **Polymorphisms in ER-alpha gene interact with estrogen receptor status in breast cancer survival**. *Clin Cancer Res* 2005, **11**:1093-1098.
73. Gonzalez-Mancha R, Galan JJ, Crespo C, Iglesias Perez L, Gonzalez-Perez A, Moron FJ, Moreno Nogueira JA, Real LM, Pascual MH, Ruiz A, Royo JL: **Analysis of the ERalpha germline PvuII marker in breast cancer risk**. *Med Sci Monit* 2008, **14**:CR136-CR143.
74. Parl FF, Cavener DR, Dupont WD: **Genomic DNA analysis of the estrogen receptor gene in breast cancer**. *Breast Cancer Res Treat* 1989, **14**:57-64.
75. Hill SM, Fuqua SA, Chamness GC, Greene GL, McGuire WL: **Estrogen receptor expression in human breast cancer associated with an estrogen receptor gene restriction fragment length polymorphism**. *Cancer Res* 1989, **49**:145-148.
76. Andersen TI, Heimdal KR, Skrede M, Tveit K, Berg K, Borresen AL: **Oestrogen receptor (ESR) polymorphisms and breast cancer susceptibility**. *Hum Genet* 1994, **94**:665-670.
77. Long JR, Kataoka N, Shu XO, Wen W, Gao YT, Cai Q, Zheng W: **Genetic polymorphisms of the CYP19A1 gene and breast cancer survival**. *Cancer Epidemiol Biomarkers Prev* 2006, **15**:2115-2122.
78. Cai Q, Shu XO, Jin F, Dai Q, Wen W, Cheng JR, Gao YT, Zheng W: **Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: Results from the Shanghai Breast Cancer Study**. *Cancer Epidemiol Biomarkers Prev* 2003, **12**:853-859.
79. Hu Z, Song CG, Lu JS, Luo JM, Shen ZZ, Huang W, Shao ZM: **A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives**. *J Cancer Res Clin Oncol* 2007, **133**:969-978.
80. Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH: **The estrogen receptor alpha gene and breast cancer risk (The Netherlands)**. *Cancer Causes Control* 2005, **16**:1195-1202.
81. Gonzalez-Zuloeta Ladd AM, Vasquez AA, Rivadeneira F, Siemes C, Hofman A, Stricker BH, Pols HA, Uitterlinden AG, van Duijn CM: **Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk**. *Breast Cancer Res Treat* 2008, **107**:415-419.
82. Shen Y, Li DK, Wu J, Zhang Z, Gao E: **Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: Results from a population-based case-control study in Shanghai, China**. *Cancer Epidemiol Biomarkers Prev* 2006, **15**:342-347.
83. Shin A, Kang D, Nishio H, Lee MJ, Park SK, Kim SU, Noh DY, Choe KJ, Ahn SH, Hirvonen A, Kim JH, Yoo KY: **Estrogen receptor alpha gene polymorphisms and breast cancer risk**. *Breast Cancer Res Treat* 2003, **80**:127-131.
84. Vord PJ, Vande, Wooley PH, Darga LL, Severson RK, Wu B, Nelson DA: **Genetic determinants of bone mass do not relate with breast cancer risk in US white and African-American women**. *Breast Cancer Res Treat* 2006, **100**:103-107.
85. Wang J, Higuchi R, Modugno F, Li J, Umblas N, Lee J, Lui LY, Ziv E, Tice JA, Cummings SR, Rhee B: **Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women**. *Breast Cancer Res Treat* 2007, **106**:273-280.
86. Wedren S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvanen AC, Kindmark A, Landegren U, Fermer ML, Stiger F, Persson I, Baron J, Weiderpass E: **Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study**. *Breast Cancer Res* 2004, **6**:R437-R449.
87. Einarsdottir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, Sjolander A, Czene K, Wedren S, Liu ET, Hall P, Humphreys K, Liu J: **ESR1 and EGF genetic variation in relation to breast cancer risk and survival**. *Breast Cancer Res* 2008, **10**:R15.
88. Cai Q, Kataoka N, Li C, Wen W, Smith JR, Gao YT, Shu XO, Zheng W: **Haplotype analyses of CYP19A1 gene variants and breast cancer risk: Results from the Shanghai Breast Cancer Study**. *Cancer Epidemiol Biomarkers Prev* 2008, **17**:27-32.
89. Buist DS, Aiello EJ, Miglioretti DL, White E: **Mammographic breast density, dense area, and breast area differences by phase in the menstrual cycle**. *Cancer Epidemiol Biomarkers Prev* 2006, **15**:2303-2306.
90. Ursin G, Parisky YR, Pike MC, Spicer DV: **Mammographic density changes during the menstrual cycle**. *Cancer Epidemiol Biomarkers Prev* 2001, **10**:141-142.
91. White E, Velentgas P, Mandelson MT, Lehman CD, Elmore JG, Porter P, Yasui Y, Taplin SH: **Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years**. *J Natl Cancer Inst* 1998, **90**:906-910.
92. Hovhannisyanyan G, Chow L, Schlosser A, Yaffe MJ, Boyd NF, Martin LJ: **Differences in measured mammographic density in the menstrual cycle**. *Cancer Epidemiol Biomarkers Prev* 2009, **18**:1993-1999.
93. Sowers MR, Wilson AL, Karvonen-Gutierrez CA, Kardia SR: **Sex steroid hormone pathway genes and health-related measures in women of 4 races/ethnicities: the Study of Women's Health Across the Nation (SWAN)**. *Am J Med* 2006, **119**:S103-S110.